William Chun Hahn MD PhD

Genitourinary Oncology, Hematologic Oncology

Professor of Medicine, Dana-Farber Cancer Institute

450 Brookline Ave# Dana-FarBoston, MA 02215
Phone+1 617-632-2641
Fax+1 617-632-4005

Dr. Hahn is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hahn's full profile Already have an account?

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1996 - 1999
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 1994 - 1997
Harvard Medical SchoolClass of 1994

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MA State Medical License 1996 - 2027
FL State Medical License 2013 - 2022

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Longitudinal Medical Record, Partners Healthcare System, 2013-2015, 2017
CMS Meaningful Use Stage 2 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2013-2015, 2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2015, 2017

Publications & Presentations

PubMed

MYC primes a paralog synthetic lethality involving the mitochondrial translocase subunits TIMM17A and TIMM17B and N-Acetylaspartate.
Sydney M Moyer, Nina Ilic, Sydney Gang, Lucas Dailey, Sehyun Oh
Science Advances. 2026-11-06
1 citations
Editorial Expression of Concern: SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2.
Kimberly H Kim, Woojin Kim, Thomas P Howard, Francisca Vazquez, Aviad Tsherniak
Nature Medicine. 2026-09-18
2 citations
O-mannosylation and protein maturation checkpoints represent therapeutic opportunities in BRAF fusion protein oncogenesis.
Anna Borgenvik, Sean A Misek, Daniel Christen, Gloria Kyrila, Alexander Zhang
Cancer Discovery. 2026-09-09

Journal Articles

Selective Gene Dependencies in MYCN-Amplified Neuroblastoma Include the Core Transcriptional Regulatory Circuitry
William C Hahn, Todd R Golub, A Thomas Look, Adam D Durbin, Neekesh V Dharia, Kimberly Stegmaier, Nature
Article Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis
William C Hahn, Levi A Garraway, Zhe Li, ScienceDirect
Germline Cancer Susceptibility Gene Variants, Somatic Second Hits, and Survival Outcomes in Patients with Resected Pancreatic Cancer
Richard F Dunne, Leona A Doyle, William C Hahn, Jason L Hornick, Andrea J Bullock, Sapna Syngal, Albert C Koong, Natalia Khalaf, Brian M Wolpin, Douglas A Rubinson, Da..., Nature

Abstracts/Posters

Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of Oncoproteins
William C. Hahn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Systematic Characterization of Genes Representing Preferential Molecular Vulnerabilities for Myeloma Cells Compared to Other Neoplasias _ Implications for the Biology ...
William C. Hahn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

Seth Karp, MD, and Gavin Dunn MD, PhD, Join Dana-Farber Cancer InstituteOctober 9th, 2026
Sonal Gandhi Joins Dana-Farber as Senior Vice President for Campus Operations and InfrastructureAugust 19th, 2026
Dana-Farber Cancer Institute Celebrates Pioneering Leadership, Honoring Former Presidents with Named Floor in Future Cancer HospitalMay 5th, 2026

Grant Support

Context-specific pathway dependencies for nuclear envelope proteins in brain cancerDANA-FARBER CANCER INST2026–2031
Investigating CREB5-driven mechanisms of immune therapy resistanceMASSACHUSETTS GENERAL HOSPITAL2024–2029
Stromal modulation of pancreatic cancer malignant cell state and therapeutic sensitivityDANA-FARBER CANCER INST2022–2027
Development of p300/CBP histone acetyltransferase inhibitors for oncogene-driven cancersBROAD INSTITUTE, INC.2022–2026
Development of p300/CBP histone acetyltransferase inhibitors for oncogene-driven cancersBROAD INSTITUTE, INC.2022–2026

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Similar Physicians & HCPs

Ting Bao, MD
OncBoston, MA
Rizwan Haq, MD
OncBoston, MA
R. Coleman Lindsley, MD
OncBoston, MA
Jose Leone, MD
OncBoston, MA
Sigurdis Haraldsdottir, MD
OncBoston, MA
Srivatsan Raghavan, MD
OncBoston, MA
Andrew Hantel, MD
OncBoston, MA
Shom Goel, MD
OncBoston, MA
Rishi Surana, MD
OncBoston, MA
Candace Haddox, MD
OncBoston, MA

Doximity / States / Massachusetts / Boston / William Hahn, MD

Dr. William Hahn, Dr. William Hahn, MD, Dr. W Hahn, Dr. William Chun Hahn